Posted by Michael Wonder on 08 Mar 2021
Health Canada approves Keytruda (pembrolizumab) as first-line treatment for adults with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer
8 March 2021 - Approval based on significant progression-free survival findings from Phase 3 KEYNOTE-177 trial.
Merck today announced that Health Canada has approved Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, for the first-line treatment, as monotherapy, for adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.
